Literature DB >> 6208551

Remission of leukemia and loss of feline leukemia virus in cats injected with Staphylococcus protein A: association with increased circulating interferon and complement-dependent cytotoxic antibody.

W T Liu, R A Good, L Q Trang, R W Engelman, N K Day.   

Abstract

We have injected purified Staphylococcus aureus protein A intraperitoneally into leukemic cats infected with feline leukemia virus, into cats persistently infected with feline leukemia virus but without hematologic or cytologic abnormalities, and into healthy cats without feline leukemia virus infection. Pre- and post-treatment serum samples were evaluated sequentially for interferon activity and for complement-dependent cytotoxic antibody. Our results indicate that serum interferon increased dramatically (less than 3 to 324 units/ml) during treatment only in cats that responded to staphylococcal protein A therapy. Increase of interferon preceded or was closely associated with increasing levels of cytotoxic antibody, loss of viremia, and correction of cytological and hematological abnormalities of three leukemic cats. The cytotoxic antibody was shown to be specific for envelope glycoprotein gp70 of the feline leukemia virus. One persistently feline leukemia virus-infected cat without leukemia that became nonviremic also developed high levels of interferon and specific cytotoxic antibody. By contrast, interferon levels of cats not responding to treatment had levels of less than 3 to 27 units/ml. Normal healthy cats injected with staphylococcal protein A showed moderate transient increases of interferon but no detectable cytotoxic antibodies to FL-74 cells. These data suggest that interferon and cytotoxic antibody may play important, possibly complementary roles in inducing remission of leukemia and loss of viremia in cats treated with staphylococcal protein A.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6208551      PMCID: PMC391946          DOI: 10.1073/pnas.81.20.6471

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  18 in total

1.  A microplaque reduction assay for human and mouse interferon.

Authors:  J B Campbell; T Grunberger; M A Kochman; S L White
Journal:  Can J Microbiol       Date:  1975-08       Impact factor: 2.419

2.  Ex vivo removal of serum IgG in a patient with colon carcinoma: some biochemical, immunological and histological observations.

Authors:  S C Bansal; B R Bansal; H L Thomas; P D Siegel; J E Rhoads; D R Cooper; D S Terman; R Mark
Journal:  Cancer       Date:  1978-07       Impact factor: 6.860

3.  Production and properties of migration inhibitory factor and interferon in the circulation of mice with delayed hypersensitivity.

Authors:  J S Youngner; S B Salvin
Journal:  J Immunol       Date:  1973-12       Impact factor: 5.422

4.  Purified human immune interferon has more potent anticellular activity than fibroblast or leukocyte interferon.

Authors:  J E Blalock; J A Georgiades; M P Langford; H M Johnson
Journal:  Cell Immunol       Date:  1980-02       Impact factor: 4.868

5.  Extensive necrosis of spontaneous canine mammary adenocarcinoma after extracorporeal perfusion over Staphylococcus aureus Cowans I. I. Description of acute tumoricidal response: morphologic, histologic, immunohistochemical, immunologic, and serologic findings.

Authors:  D S Terman; T Yamamoto; M Mattioli; G Cook; R Tillquist; J Henry; R Poser; Y Daskal
Journal:  J Immunol       Date:  1980-02       Impact factor: 5.422

6.  Inhibition of TRIC agents by virus-induced interferon.

Authors:  L Hanna; T C Merigan; E Jawetz
Journal:  Proc Soc Exp Biol Med       Date:  1966-06

7.  Electrophoretically pure mouse interferon exerts multiple biologic effects.

Authors:  I Gresser; J De Maeyer-Guignard; M G Tovey; E De Maeyer
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

8.  Treatment of feline leukemia and reversal of FeLV by ex vivo removal of IgG: a preliminary report.

Authors:  F R Jones; L H Yoshida; W C Ladiges; M A Kenny
Journal:  Cancer       Date:  1980-08-15       Impact factor: 6.860

9.  Large-scale production and physicochemical characterization of human immune interferon.

Authors:  M P Langford; J A Georgiades; G J Stanton; F Dianzani; H M Johnson
Journal:  Infect Immun       Date:  1979-10       Impact factor: 3.441

10.  Feline preleukemia: an animal model of human disease.

Authors:  L Maggio; R Hoffman; S M Cotter; N Dainiak; S Mooney; L A Maffei
Journal:  Yale J Biol Med       Date:  1978 Jul-Aug
View more
  6 in total

Review 1.  Feline leukemia virus: current status of the feline induced immune depression and immunoprevention.

Authors:  R G Olsen; M G Lewis; L J Lafrado; L E Mathes; K Haffer; R Sharpee
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

2.  Influence of inactivated feline retrovirus on feline alpha interferon and immunoglobulin production.

Authors:  M Yasuda; R A Good; N K Day
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

3.  Characterization of a newly established feline lymphoma-derived cell line (BKD) lacking T and B cell surface markers.

Authors:  R W Engelman; K Machida; R E Longley; W T Liu; L Q Trang; R A Good; N K Day
Journal:  In Vitro Cell Dev Biol       Date:  1986-05

4.  Effects of cobra venom factor treatment on latent feline leukemia virus infection.

Authors:  E H Kraut; J L Rojko; R G Olsen; D L Tuomari
Journal:  J Virol       Date:  1985-06       Impact factor: 5.103

5.  Clinicopathologic responses in cats with feline leukemia virus-associated leukemia-lymphoma treated with staphylococcal protein A.

Authors:  R W Engelman; R D Tyler; L Q Trang; W T Liu; R A Good; N K Day
Journal:  Am J Pathol       Date:  1985-03       Impact factor: 4.307

6.  Alpha interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome.

Authors:  N S Zeidner; M H Myles; C K Mathiason-DuBard; M J Dreitz; J I Mullins; E A Hoover
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.